Roland J. Fuchs

RWTH Aachen University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

George J. Demko

Dartmouth College

Harald Gerhold

W. Gaßmann

Malteser Krankenhaus St. Anna

Andreas Hochhaus

Jena University Hospital

Günter Gruber

Graz University of Technology

Bernd Stojanovic

Erhard Hiller

Praxis für Hämatologie und Onkologie

Dieter K. Hossfeld

University Medical Center Hamburg-Eppendorf

H Gerhartz

European Organisation for Research and Treatment of Cancer

Rüdiger Hehlmann

Heidelberg University

Cooperative Institutions

Heidelberg University

131

Praxis für Hämatologie und Onkologie

124

University Hospital Heidelberg

Ludwig-Maximilians-Universität München

Charité - Universitätsmedizin Berlin

Universität Hamburg

University of Münster

University Medical Center Hamburg-Eppendorf

Medizinische Hochschule Hannover

Heinrich Heine University Düsseldorf

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma

European Journal of Cancer and Clinical Oncology (1989)

G. Blackledge Jaap Verweij Roland J. Fuchs H.J. Keizer R. Somers

Topotecan

10.1016/0277-5379(89)90366-0

Cite

Citations (6)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Leukemia (2017)

Rüdiger Hehlmann Michael Lauseker Susanne Saußele Markus Pfirrmann Stefan W. Krause

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

Hematology

Imatinib Mesylate

10.1038/leu.2017.253

Cite

Citations (279)

Global-Regional Linkages in the Earth System

Springer eBooks (2002)

Peter Tyson Congbin Fu Roland J. Fuchs Louis Lebel Abhijit Mitra

Earth system science

Biogeochemical Cycle

Global Change

10.1007/978-3-642-56228-0

Cite

Citations (53)

DIAGNOSTIC POSSIBILITIES FOR THE EARLY RECOGNITION OF DANGEROUS JAUNDICE OF THE NEWBORN

A. Kluge Roland J. Fuchs Ehrenfried Schindler

Source

Cite

Citations (2)

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Haematologica (2018)

Christian Michel Andreas Burchert Andreas Hochhaus Susanne Saußele Andreas Neubauer

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg ('high-dose') imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. To gain insights into this clinically relevant question, we analyzed the outcome of imatinib dose reductions from 800 mg to 400 mg daily in the Chronic Myeloid Leukemia-Study IV. Of the 422 patients that were randomized to the 800 mg arm, 68 reduced imatinib to 400 mg after they had achieved at least a stable major molecular response. Of these 68 patients, 61 (90%) maintained major molecular remission on imatinib at 400 mg. Five of the seven patients who lost major molecular remission on the imatinib standard dose regained major molecular remission while still on 400 mg imatinib. Only two of 68 patients had to switch to more potent kinase inhibition to regain major molecular remission. Importantly, the lengths of the intervals between imatinib high-dose treatment before and after achieving major molecular remission were associated with the probabilities of maintaining major molecular remission with the standard dose of imatinib. Taken together, the data support the view that a deep molecular remission achieved with high-dose imatinib can be safely maintained with standard dose in most patients. Study protocol registered at clinicaltrials.gov 00055874.

Chronic myelogenous leukemia

Imatinib Mesylate

10.3324/haematol.2018.206797

Cite

Citations (21)

Characterization of two new fusion genes in the 8p11 myeloproliferative syndrome (EMS) generated by disruption of FGFR

Alyssa Reiter Christoph Walz Claudia Schoch Andrew Chase Roland J. Fuchs

Source

Cite

Citations (0)

Bhutan: A Physical and Cultural Geography

Economic Geography (1968)

Roland J. Fuchs Pradyumna P. Karan

10.2307/142771

Cite

Citations (14)

Risk Factor Adapted Treatment of Hodgkin’s Lymphoma: Strategies and Perspectives

Recent results in cancer research/Recent Results in Cancer Research (1989)

Markus Loeffler Michael Pfreundschuh U Rühl Erhard Hiller H Gerhartz

COPP

ABVD

B symptoms

Salvage therapy

Induction chemotherapy

10.1007/978-3-642-83781-4_15

Cite

Citations (21)

Demography and Urban and Regional Planning in Northeastern Europe

Routledge eBooks (2019)

George J. Demko Roland J. Fuchs

This chapter addresses the interrelationship of demography and regional and urban planning and focuses on contemporary spatial demographic issues in North-eastern Europe. The nations treated—Czechoslovakia, the German Democratic Republic, Hungary, and Poland—are the most advanced Eastern European nations in terms of the industrial revolution and the demographic transition. In the planned socialist societies, the study of demography assumes a unique character, one imposed by the objectives of socialism and the requirements of comprehensive economic planning. In the planning process, the demographic components at the regional and local level must be closely interrelated to economic components of national and sectoral level plans. The demographic sciences are called upon to help identify desirable or optimal future population and settlement distribution patterns, to identify problems created by the discrepancies between current realities and desired goals, and to help form policy instruments or mechanisms to aid in achieving the goals.

10.4324/9780429302619-4

Cite

Citations (2)

[The histologic types of bronchial carcinoma with reference to Kreyberg's classification].

PubMed (1966)

Riccardo Haupt Roland J. Fuchs

Source

Cite

Citations (0)